MX2024006300A - Inhibidores de aminoheteroaril cinasa. - Google Patents
Inhibidores de aminoheteroaril cinasa.Info
- Publication number
- MX2024006300A MX2024006300A MX2024006300A MX2024006300A MX2024006300A MX 2024006300 A MX2024006300 A MX 2024006300A MX 2024006300 A MX2024006300 A MX 2024006300A MX 2024006300 A MX2024006300 A MX 2024006300A MX 2024006300 A MX2024006300 A MX 2024006300A
- Authority
- MX
- Mexico
- Prior art keywords
- aminoheteroaryl
- kinase inhibitors
- compounds
- cdks
- disorders
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
- A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D309/10—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/16—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D309/20—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hydrogen atoms and substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D309/22—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Control Of El Displays (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2020132454 | 2020-11-27 | ||
| CN2021081236 | 2021-03-17 | ||
| PCT/CN2021/133429 WO2022111621A1 (en) | 2020-11-27 | 2021-11-26 | Aminoheteroaryl kinase inhibitors |
| PCT/CN2022/133770 WO2023093769A1 (en) | 2020-11-27 | 2022-11-23 | Aminoheteroaryl kinase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2024006300A true MX2024006300A (es) | 2024-07-24 |
Family
ID=81753779
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024006300A MX2024006300A (es) | 2020-11-27 | 2022-11-23 | Inhibidores de aminoheteroaril cinasa. |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US20240166635A1 (https=) |
| EP (2) | EP4251613A4 (https=) |
| JP (2) | JP2024506116A (https=) |
| KR (1) | KR20230127228A (https=) |
| CN (2) | CN116528869B (https=) |
| AU (3) | AU2021385745C1 (https=) |
| CA (2) | CA3202990A1 (https=) |
| IL (1) | IL303237A (https=) |
| MX (1) | MX2024006300A (https=) |
| WO (2) | WO2022111621A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4251613A4 (en) * | 2020-11-27 | 2024-11-20 | Allorion Therapeutics Inc. | AMINOHETEROARYL KINASE INHIBITORS |
| CA3207392A1 (en) * | 2021-02-05 | 2022-08-11 | Xiaoxia Yan | Cdk inhibitor |
| EP4532473A1 (en) * | 2022-05-27 | 2025-04-09 | Allorion Therapeutics Inc. | Aminoheteroaryl kinase inhibitors |
| WO2025006400A1 (en) * | 2023-06-25 | 2025-01-02 | Allorion Therapeutics Inc | Isotopologues of aminoheteroaryl kinase inhibitors and uses thereof |
| WO2026024674A1 (en) | 2024-07-22 | 2026-01-29 | Genesis Therapeutics, Inc. | Methods of treating skp2-associated cancers |
| EP4725942A1 (en) * | 2024-10-09 | 2026-04-15 | Sibylla Biotech S.p.A. | Compounds active on cyclin d1 pathway and their use |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0004890D0 (en) * | 2000-03-01 | 2000-04-19 | Astrazeneca Uk Ltd | Chemical compounds |
| GB0004888D0 (en) * | 2000-03-01 | 2000-04-19 | Astrazeneca Uk Ltd | Chemical compounds |
| GB0016877D0 (en) * | 2000-07-11 | 2000-08-30 | Astrazeneca Ab | Chemical compounds |
| GB0021726D0 (en) * | 2000-09-05 | 2000-10-18 | Astrazeneca Ab | Chemical compounds |
| BR0116452A (pt) * | 2000-12-21 | 2003-09-30 | Glaxo Group Ltd | Composto, composição farmacêutica, uso de um composto |
| BR0209774A (pt) * | 2001-05-29 | 2004-06-01 | Schering Ag | Pirimidinas inibidoras de cdk, sua preparação e aplicação como medicamento |
| GB0113041D0 (en) * | 2001-05-30 | 2001-07-18 | Astrazeneca Ab | Chemical compounds |
| IL161663A0 (en) * | 2001-11-01 | 2004-09-27 | Janssen Pharmaceutica Nv | AMINOBENZAMIDE DERIVATIVES AS GLYCOGEN SYNTHASE KINASE 3beta INHIBITORS |
| GB0205693D0 (en) * | 2002-03-09 | 2002-04-24 | Astrazeneca Ab | Chemical compounds |
| GB0205688D0 (en) * | 2002-03-09 | 2002-04-24 | Astrazeneca Ab | Chemical compounds |
| EP1483260A1 (de) * | 2002-03-11 | 2004-12-08 | Schering Aktiengesellschaft | Cdk inhibitorische 2-heteroaryl-pyrimidine, deren herstellung und verwendung als arzneimittel |
| JP2006508997A (ja) * | 2002-11-28 | 2006-03-16 | シエーリング アクチエンゲゼルシャフト | Ｃｈｋ−、Ｐｄｋ−およびＡｋｔ−阻害性ピリミジン、それらの製造および薬剤としての使用 |
| US7504396B2 (en) * | 2003-06-24 | 2009-03-17 | Amgen Inc. | Substituted heterocyclic compounds and methods of use |
| DE102005008310A1 (de) * | 2005-02-17 | 2006-08-24 | Schering Ag | Verwendung von CDKII Inhibitoren zur Fertilitätskontrolle |
| AU2006244195B2 (en) * | 2005-05-05 | 2012-03-15 | Ardea Biosciences, Inc. | Diaryl-purine, azapurines and -deazapurines as non-nucleoside reverse transcriptase inhibitors for treatment of HIV |
| AU2007338792B2 (en) * | 2006-12-20 | 2012-05-31 | Amgen Inc. | Substituted heterocycles and methods of use |
| CN101679440A (zh) * | 2007-04-02 | 2010-03-24 | 帕劳制药股份有限公司 | 作为jak3抑制剂的吡咯并嘧啶衍生物 |
| WO2008128231A1 (en) * | 2007-04-16 | 2008-10-23 | Hutchison Medipharma Enterprises Limited | Pyrimidine derivatives |
| CN101678215B (zh) * | 2007-04-18 | 2014-10-01 | 辉瑞产品公司 | 用于治疗异常细胞生长的磺酰胺衍生物 |
| WO2009022171A1 (en) * | 2007-08-13 | 2009-02-19 | Astrazeneca Ab | Pyridinyiioxy pyridines as alk5 inhibitors |
| EP2179992A1 (de) * | 2008-10-21 | 2010-04-28 | Bayer Schering Pharma Aktiengesellschaft | Sulfonsubstituierte Anlinopyrimidinderivative als CDK-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel |
| TW201024281A (en) * | 2008-11-24 | 2010-07-01 | Boehringer Ingelheim Int | New compounds |
| DE102010014426A1 (de) * | 2010-04-01 | 2011-10-06 | Bayer Schering Pharma Aktiengesellschaft | Verwendung neuer pan-CDK-Inhibitoren zur Behandlung von Tumoren |
| US9145402B2 (en) * | 2011-11-29 | 2015-09-29 | Genentech, Inc. | Aminopyrimidine derivatives as LRRK2 modulators |
| NZ629830A (en) * | 2014-07-14 | 2015-12-24 | Signal Pharm Llc | Methods of treating a cancer using substituted pyrrolopyrimidine compounds, compositions thereof |
| CN110386901B (zh) * | 2018-04-23 | 2022-11-25 | 上海医药工业研究院 | 含磺酰苯胺嘧啶结构的化合物及其作为抗肿瘤药物的应用 |
| WO2019213340A1 (en) * | 2018-05-03 | 2019-11-07 | Bristol-Myers Squibb Company | Uracil derivatives as mer-axl inhibitors |
| WO2020205560A1 (en) * | 2019-03-29 | 2020-10-08 | Incyte Corporation | Sulfonylamide compounds as cdk2 inhibitors |
| EP4110782A1 (en) * | 2020-02-28 | 2023-01-04 | Fochon Biosciences, Ltd. | Compounds as cdk2/4/6 inhibitors |
| US20230411615A1 (en) * | 2020-11-04 | 2023-12-21 | Umicore | A positive electrode active material for rechargeable batteries |
| EP4251613A4 (en) * | 2020-11-27 | 2024-11-20 | Allorion Therapeutics Inc. | AMINOHETEROARYL KINASE INHIBITORS |
| CA3207392A1 (en) * | 2021-02-05 | 2022-08-11 | Xiaoxia Yan | Cdk inhibitor |
-
2021
- 2021-11-26 EP EP21897121.6A patent/EP4251613A4/en active Pending
- 2021-11-26 WO PCT/CN2021/133429 patent/WO2022111621A1/en not_active Ceased
- 2021-11-26 IL IL303237A patent/IL303237A/en unknown
- 2021-11-26 CA CA3202990A patent/CA3202990A1/en active Pending
- 2021-11-26 US US18/254,573 patent/US20240166635A1/en active Pending
- 2021-11-26 AU AU2021385745A patent/AU2021385745C1/en active Active
- 2021-11-26 KR KR1020237021724A patent/KR20230127228A/ko active Pending
- 2021-11-26 CN CN202180079929.6A patent/CN116528869B/zh active Active
- 2021-11-26 JP JP2023531615A patent/JP2024506116A/ja active Pending
-
2022
- 2022-11-23 AU AU2022397678A patent/AU2022397678A1/en active Pending
- 2022-11-23 CN CN202280077473.4A patent/CN118475562A/zh active Pending
- 2022-11-23 MX MX2024006300A patent/MX2024006300A/es unknown
- 2022-11-23 CA CA3238970A patent/CA3238970A1/en active Pending
- 2022-11-23 EP EP22897852.4A patent/EP4436959A4/en active Pending
- 2022-11-23 WO PCT/CN2022/133770 patent/WO2023093769A1/en not_active Ceased
- 2022-11-23 JP JP2024531423A patent/JP2024541533A/ja active Pending
-
2024
- 2024-05-21 US US18/670,469 patent/US20250002480A1/en active Pending
-
2025
- 2025-01-02 AU AU2025200001A patent/AU2025200001A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2021385745B2 (en) | 2024-10-03 |
| CN116528869A (zh) | 2023-08-01 |
| US20250002480A1 (en) | 2025-01-02 |
| EP4436959A1 (en) | 2024-10-02 |
| EP4436959A4 (en) | 2026-02-11 |
| JP2024506116A (ja) | 2024-02-09 |
| CN118475562A (zh) | 2024-08-09 |
| AU2021385745A9 (en) | 2025-03-27 |
| EP4251613A4 (en) | 2024-11-20 |
| CN116528869B (zh) | 2026-04-14 |
| AU2025200001A1 (en) | 2025-01-23 |
| US20240166635A1 (en) | 2024-05-23 |
| CA3238970A1 (en) | 2023-06-01 |
| IL303237A (en) | 2023-07-01 |
| EP4251613A1 (en) | 2023-10-04 |
| JP2024541533A (ja) | 2024-11-08 |
| WO2022111621A1 (en) | 2022-06-02 |
| KR20230127228A (ko) | 2023-08-31 |
| AU2021385745C1 (en) | 2025-02-20 |
| WO2023093769A1 (en) | 2023-06-01 |
| AU2022397678A1 (en) | 2024-05-30 |
| CA3202990A1 (en) | 2022-06-02 |
| AU2021385745A1 (en) | 2023-06-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2024006300A (es) | Inhibidores de aminoheteroaril cinasa. | |
| MX2025011774A (es) | Compuestos de imidazolil pirimidinilamina como inhibidores de cdk2 | |
| MX2020014245A (es) | Inhibidores de quinasas dependientes de ciclinas. | |
| MX2025011533A (es) | Aminas biciclicas como inhibidores de la cinasa dependiente de ciclina 2 (cdk2) | |
| JOP20230272A1 (ar) | مركبات تثبيط rip1 وطرق لتحضير واستخدامها | |
| JOP20200277B1 (ar) | مركبات تثبيط rip1 وطرق لتحضير واستخدامها | |
| ZA202204284B (en) | Inhibitors of raf kinases | |
| AU2020281332A8 (en) | Dna-dependent protein kinase inhibitor | |
| PH12020550986A1 (en) | Heterocyclylamino-substituted triazoles as modulators of rho-associated protein kinase | |
| WO2020093006A8 (en) | Methods of treating cancer in biomarker-identified patients with non-covalent inhibitors of cyclin-dependent kinase 7 (cdk7) | |
| CN106687454B8 (zh) | 作为细胞周期蛋白依赖性激酶(cdk)抑制剂的2h-吲唑衍生物及其医疗用途 | |
| SA522441624B1 (ar) | مثبطات إنزيمات كيناز مستقبل عامل نمو الأرومة الليفية | |
| PH12023552079A1 (en) | Cdk2 inhibitors and methods of using the same | |
| MX2025001108A (es) | Inhibidores de cinasas aminoheteroarílicos. | |
| MX2024015581A (es) | Derivados de anilino-pirazol, composiciones y metodos de estos | |
| PH12021551304A1 (en) | Tyrosine kinase inhibitors, compositions and methods there of | |
| PH12022551623A1 (en) | Substituted pyrazolo-pyrimidines and uses thereof | |
| GB201302704D0 (en) | Therapeutic compounds | |
| MX2023003516A (es) | Inhibidores no covalentes de la cinasa dependiente de ciclina 7 (cdk7). | |
| MX2025009633A (es) | Inhibidores de quinasa dependientes de ciclina (cdk2) | |
| JOP20220355A1 (ar) | مثبطات rip1k | |
| MX2024013266A (es) | Compuestos de 6-(pirimidin-4-il)quinolina sustituidos como inhibidores de la cinasa dependiente de ciclina | |
| MX2025013034A (es) | Inhibidores de egfr para el tratamiento de enfermedades | |
| GEP20227437B (en) | 1h-indazole-3-carboxamide compounds as glycogen synthase kinase 3 beta inhibitors | |
| MX2022001702A (es) | Inhibidores de jak. |